Most in U.S. are Unaware of Recent Shortages of Cancer Therapies, Survey Says
Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer…
News
Tilsotolimod and Yervoy Combo Seen to Shrink Tumors in Pre-treated Metastatic Melanoma Patients in Ongoing Phase 2 Trial
A combination of Idera Pharmaceuticals’s treatment candidate tilsotolimod plus Yervoy (ipilimumab) is able to reduce tumors in a group of patients with refractory…
Pomalyst Triple Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients, Phase 3 Data Show
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended…
Janssen Halts Clinical Trials of Darzalex with PD-1/PD-L1 Inhibitors Amid Concerns Over Safety, Effectiveness
Janssen has decided to discontinue a Phase 1 trial assessing Darzalex (daratumumab) in combination with JNJ-63723283 — an anti-PD-1 antibody — in multiple myeloma patients, …
Trial Data Supports Darzalex Combo as Potentially Effective in Myeloma Patients Who Don’t Respond to Revlimid
A combination of Darzalex (daratumumab) plus Kyprolis (carfilzomib) and dexamethasone is well-tolerated and may be effective in multiple myeloma patients who fail to respond to treatment…
Canadian Researchers Launch Study to Make Stem Cell Transplants Safer, More Efficient
Researchers in Canada are studying how to reduce the risks associated with the treatment of multiple myeloma by improving the safety and efficacy of…
MS Therapy May Ease Painful Side Effect of Velcade Treatment in Myeloma Patients, Study Says
A multiple sclerosis (MS) treatment reduced a common painful side effect of Velcade (bortezomib) in a mouse model, suggesting that it might help…
Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018
Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated…
Recruitment Open for Phase 2 Trial Aimed at Complete Eradication of Myeloma Cells
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an…
FDA Names Cancer Vaccine Galinpepimut-S Orphan Drug as Possible Multiple Myeloma Treatment
The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of…
